Board Meeting Details

The Board meeting was held on July 28, 2026, commencing at 11:30 AM and concluding at 2:30 PM IST.

Key Decisions Approved

1. Unaudited Standalone Financial Results for Q1 FY27

  • Approved the unaudited standalone financial results for the quarter ended June 30, 2026 (Q1 FY27)
  • Results were reviewed by the statutory auditors who issued a limited review report
  • The financial results are annexed as Annexure A to the disclosure

2. 37th Annual General Meeting

  • Approved convening the 37th Annual General Meeting (AGM) on Friday, September 25, 2026, at 10:30 AM IST
  • The AGM will be conducted through videoconferencing
  • The Notice of AGM and Annual Report will be released in due course
  • Shareholders are requested to update their information with depositories (for demat holdings) or with the Company's RTA (for physical holdings) to receive communications via email

Financial Results Summary (Quarter Ended June 30, 2026)

Income Statement (₹ in lakhs)

  • Revenue from operations: ₹959.64 (vs. ₹863.91 in Q1 FY26)
  • Other operating income: ₹101.58 (primarily rentals for Biotech facility and equipment leased to Sun Pharmaceutical Industries Limited for R&D activities)
  • Other income: ₹43.57
  • Total income: ₹1,104.79

Expenses (₹ in lakhs)

  • Employee benefit expenses: ₹491.63
  • Depreciation and amortization expense: ₹190.23
  • Other expenses: ₹483.00
  • Total expenses: ₹1,164.86

Profit/(Loss)

  • Loss before exceptional items and tax: ₹(60.07)
  • Exceptional items: Nil
  • Loss before tax: ₹(60.07)
  • Tax expense: ₹(14.52) (deferred tax benefit)
  • Net loss for the quarter: ₹(45.55)
  • Other comprehensive income: ₹1.17
  • Total comprehensive income for the period: ₹(44.38)

Earnings Per Share

  • Basic EPS: ₹(0.07)
  • Diluted EPS: ₹(0.07)

Comparative Figures

  • Q1 FY26 (June 30, 2025): Net profit of ₹98.96 lakh
  • Q4 FY26 (March 31, 2026): Net loss of ₹315.08 lakh
  • Full year FY26: Net loss of ₹107.21 lakh

Capital Structure

  • Paid-up equity share capital: ₹6,103.06 lakh (face value ₹10 per share)
  • Reserves/other equity: ₹3,409.05 lakh (as of March 31, 2026)

Additional Notes from Financial Statements

1. The financial results were drawn up in accordance with Regulation 33 of SEBI (LODR) Regulations, 2015, reviewed by the Audit Committee and approved by the Board on July 28, 2026.

2. The results were prepared in accordance with Indian Accounting Standards (Ind AS).

3. Majority of matters relating to financial and non-financial irregularities pertaining to periods prior to November 12, 2011, were abated/settled. The Company believes any financial impact from these legacy matters is not material.

4. Overseas subsidiaries (Zenotech Farmaceutica Do Brasil Ltda and Zenotech Inc) were reported as cancelled/revoked based on certificates received in June 2022. Zenotech Laboratories Nigeria Limited winding up order was received in FY 2019-20 (RBI filings pending). The Company believes it has no subsidiaries, joint ventures or associates within the definition of Ind AS 110.

5. Other operating income relates to rentals for Biotech facility and equipment leased to Sun Pharmaceutical Industries Limited for R&D activities.

6. The Company has only one reportable segment: Pharmaceuticals.

7. The quarter ended March 31, 2026 figures are balancing figures between audited full year and unaudited published figures for nine months.

8. Previous period/year figures have been regrouped to conform to current period presentation.

Auditor's Review Report

  • G S K A & Co., Chartered Accountants (Registration Number: 147093W) conducted the review
  • Review performed in accordance with Standard on Review Engagements (SRE) 2410
  • Expressed an unmodified conclusion: "Nothing has come to our attention that causes us to believe that the accompanying Statement... contains any material misstatement"
  • Signed by Partner Gangsh Gaikwad (Membership Number: 136512) in Pune on July 28, 2026